The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Werewolf Therapeutics (NASDAQ:HOWL) has been analyzed by 4 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish sentiments. The average 12-month price target is $13.5, with a high of $15.00 and a low of $12.00, marking a 10% decline from the previous target. The company's financial health indicates a strong market presence but challenges in revenue growth, profitability, and asset utilization. Analysts' ratings and price targets reflect their perceptions and reactions to the company's performance and market conditions.
May 06, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Werewolf Therapeutics has received mixed analyst ratings, with an updated average price target of $13.5. Financial indicators show a strong market cap but declining revenue and challenges in profitability and asset utilization.
The mixed analyst ratings and the adjustment in price targets suggest a cautious but not pessimistic outlook for Werewolf Therapeutics. The financial health of the company, marked by a significant market presence but declining revenue and challenges in profitability, may lead to short-term volatility in the stock price. However, the absence of bearish sentiments among analysts could stabilize investor confidence, leading to a neutral short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100